Extreme Networks Schedules Third Quarter Fiscal 2023 Financial Results Conference Call

Extreme Networks Schedules Third Quarter Fiscal 2023 Financial Results Conference Call

MORRISVILLE, N.C.–(BUSINESS WIRE)–Extreme Networks, Inc. (Nasdaq: EXTR), a leader in cloud networking, today announced plans to release financial results for its third fiscal quarter, ended March 31, 2023. The company will announce before market open on Wednesday, April 26, 2023, followed by an earnings conference call and webcast at 8:00 a.m. ET.

The details for the webcast are:

When:

Wednesday, April 26 at 8:00 a.m. ET (5:00 a.m. PT)

Where:

http://investor.extremenetworks.com/

Dial in:

To access the call by phone, please go to this link (Registration Link)and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

About Extreme Networks:

Extreme Networks, Inc. (EXTR) is a leader in cloud networking focused on delivering services that connect devices, applications, and people in new ways. We push the boundaries of technology leveraging the powers of machine learning, artificial intelligence, analytics, and automation. 50,000 customers globally trust our end-to-end, cloud-driven networking solutions and rely on our top-rated services and support to accelerate their digital transformation efforts and deliver progress like never before. For more information, visit Extreme’s website at https://www.extremenetworks.com/ or follow us on LinkedIn, YouTube, Twitter, Facebook or Instagram.

Extreme Networks and the Extreme Networks logo are trademarks or registered trademarks of Extreme Networks, Inc. in the United States and other countries.

Investor Relations and Press Contacts:

Stan Kovler

Vice President, Corporate Strategy & Investor Relations

Extreme Networks

919-595-4196

[email protected]

Amy Aylward

Vice President, Corporate Marketing

Extreme Networks

603-952-5138

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Professional Services Technology Data Analytics Networks Artificial Intelligence Internet

MEDIA:

Logo
Logo

Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Med

EDEN PRAIRIE, Minn., April 10, 2023 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that CEO Jeff Ross, Ph.D will present at the 2023 Cell & Gene Meeting on the Mediterranean. The conference will be held April 12 – 14 in Barcelona, Spain, bringing together leading public and private sector cell and gene therapy companies.

Dr. Ross will moderate a panel entitled The Pioneer Tax: Challenges and Opportunities of Being at the Forefront of Innovation beginning at 2:00pm CET on Thursday, April 13th. Following the panel discussion, Dr. Ross will deliver a company presentation at 3:30pm CET. Both appearances will take place in the BioCentriq Ballroom and will be live-streamed for virtual attendees. Recordings will be available within 24 hours for further on-demand viewing.

“I am honored to be a part of Meeting on the Med for another year alongside thought leaders from across the cell and gene therapy industry,” said Jeff Ross, Miromatrix CEO. “Miromatrix’s proprietary bioengineered organs are at the forefront of technologies that could transform the transplant industry, and we are hopeful our solution may someday help address the shortage of human organs available for transplant and bring a cure to patients in need.”

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program features expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 60+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies. Over 500 attendees are expected to take part in the 2023 hybrid conference.

Registration for the conference is available here.

About Miromatrix

Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Miromatrix Contacts

Investor Relations
Greg Chodaczek
347-620-7010
[email protected]

Media Relations
Christina Campbell
612-924-3793
[email protected]



Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

  • Exhibition will run from March 31

    st

    to May 21

    st

    , 2023, at Prada Rong Zhai
  • Scientific Conference will be held on April 20

    th

    , 2023,
    at Prada Rong Zhai

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that poster presentations on intranasal foralumab are being presented at the “Preserving the Brain” scientific conference and exhibit held at the Fondazione Prada in Rong Zhai in Shanghai.

“Preserving the Brain” is a scientific forum and exhibit on neurodegenerative diseases as part of the “Human Brains” neuroscience project held in Fondazione Prada in Shanghai, China. In collaboration with thirteen of the most relevant international neuroscience institutes and universities, the aim of this event is to stimulate an open and critical exchange between international scientists and experts on neurodegenerative diseases.

“I am absolutely thrilled that foralumab has once again been invited to be presented at the Fondazione Prada’s “Preserving the Brain” international forum, this year being held in Shanghai,” commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana Life Sciences. “Having our lead asset Foralumab, the only fully human anti-CD3 highlighted again at an esteemed cultural institution such as Fondazione Prada only further validates our passion and focus to advance this novel therapy in neuroinflammatory diseases.”

About Foralumab

Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd

Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: [email protected]

Investors:

Irina Koffler
LifeSci Advisors, LLC
646.970.4681
[email protected]

_____________________________

1 https://www.pnas.org/doi/10.1073/pnas.2220272120

 



Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other Central Nervous System (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the 22nd Annual Needham Virtual Healthcare Conference 2023 on Monday, April 17, 2023, at 8:00 AM ET.

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and recently a Phase 2b/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter,Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: [email protected]

Investors:

Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: [email protected]



Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT.

A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:

Annie Spinetta
6 Degrees
973-768-2170
[email protected]

INVESTOR CONTACT:

Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
[email protected]



TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance

Company also announces key leadership promotions

WALTHAM, Mass., April 10, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Barbara Klencke, M.D., to its Board of Directors, effective April 6, 2023. Dr. Klencke is an accomplished oncology drug developer with a demonstrated track record of success, having made substantial contributions to the development and approval of numerous oncology products.

“I am pleased to welcome Barbara, a highly respected and experienced leader in oncology, as an independent director to the TScan Board,” said Gavin MacBeath, Ph.D., acting Chief Executive Officer and Chief Scientific and Operating Officer. “As Chief Medical Officer and Chief Development Officer of a late-stage biopharmaceutical company focusing on advancing targeted therapeutics for the treatment of rare cancers, Barbara brings extensive experience that will be critical in the next phase of the Company’s growth. The addition of Dr. Klencke comes at an exciting time for our Company as we continue to deliver on our focused clinical pipeline with multiple value inflection points in solid tumors and hematologic malignancies throughout 2023. We look forward to her contributions.”

“I am delighted to be joining TScan Therapeutics’ board as I share the Company’s commitment to creating life-changing T cell therapies for patients in need. I am grateful to be working alongside an accomplished team of industry veterans and look forward to contributing to the progress already underway, helping to support the advancement of the Company’s compelling scientific pipeline,” commented Dr. Klencke.

Dr. Klencke is a seasoned executive with more than 20 years of experience across both pharmaceutical and biotech companies. She most recently served as the Chief Medical and Chief Development Officer of Sierra Oncology Inc., which was acquired by GlaxoSmithKline in 2022. Dr. Klencke has served as an independent board member of eFFECTOR Therapeutics, Inc. since 2021, Immune-Onc Therapeutics, Inc. since 2022, and Lexent Bio, Inc. from 2017 until the company’s acquisition by Foundation Medicine, Inc. in 2020. From 2011 to 2015, Dr. Klencke served as Senior Vice President, Global Development at Onyx Pharmaceuticals Inc., which was acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs during her tenure at Genentech, Inc. from 2003 to 2011. Throughout her career, she has played a major role in the successful development, approval and early commercialization of a number of important oncology products. Dr. Klencke completed her Internal Medicine and Hematology and Oncology training at the University of California, San Francisco and remained there as an Assistant Professor of Medicine in Oncology, focusing on clinical research, from 1995 to 2002. She holds a Bachelor of Science from Indiana University and a Doctor of Medicine from the University of California, Davis.

Key Leadership Promotions

“At TScan, we believe it is of paramount importance to harness the strengths of our executive management team as we navigate our first clinical trials across hematologic malignancies and solid tumors,” said Brian Silver, J.D., Chief Financial Officer. “These key promotions highlight the strength of our in-house team as our clinical-stage oncology programs advance.”

Shrikanta Chattopadhyay, M.D., M.M.Sc., has been promoted to Senior Vice President, Medical, Translational Medicine. Dr. Chattopadhyay has over 15 years of experience in drug discovery and drug development in academic and industry settings. Prior to joining TScan, Shri was a board-certified hematologist-oncologist at Massachusetts General Hospital, physician-scientist at the Broad Institute of MIT and Harvard and a clinical consultant for venture capital and biotechnology companies. In addition to clinical practice, he oversaw a broad spectrum of research efforts including preclinical drug discovery, first-in-human and later phase clinical trials. Shri began consulting for TScan in 2019 and was inspired to join full time in January 2021. He obtained his M.D. at the All India Institute of Medical Sciences and his Master of Medical Sciences in clinical investigation at Harvard Medical School. Shri completed his residency training in internal medicine at the Albert Einstein College of Medicine and his clinical fellowship in hematology/oncology at the Dana-Farber Cancer Institute.

Ann Hargraves has been promoted to Senior Vice President, Human Resources. Ann has over 20 years of experience building and leading teams. Prior to joining TScan, Ann founded Mindset Consulting, working to build the people strategy and capability for businesses in multiple industries. Before founding Mindset, Ann was the Head of Human Resources at Kettle Cuisine, through multiple acquisitions and divestitures. Before joining Kettle Cuisine, Ann led Human Resources for Keurig where she was instrumental in building a nationally recognized culture and high performing teams that contributed to Keurig’s hyper growth and success. Previously, Ann was the Vice President of Operations at an independent publishing company. Ann is an S.P.H.R. and holds a B.S. in Psychology from Salem State College.

Ray Lockard, M.B.A., has been promoted to Senior Vice President, Technical Operations and Quality. Ray brings to TScan over 25 years of experience in quality, validation, supply chain and manufacturing. Prior to joining TScan, Ray served as Executive Director, CMC, QA and External Quality at Ultragenyx Pharmaceutical Inc. Before joining Ultragenyx, he was the Quality Site Head for the AveXis (now Novartis Gene Therapies) gene therapy manufacturing facility in Raleigh N.C. Prior to that, Ray held positions of increasing responsibility for various biotechnology and life sciences companies including Biogen Inc., Alnylam Pharmaceuticals, Inc., Precision NanoSystems, and Editas Medicine, Inc. Ray holds a B.S. in Biology from Hampden-Sydney College and an M.B.A. from the University of North Carolina, Chapel Hill, Kenan-Flagler Business School.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, progress, and timing relating to the Company’s hematologic malignancies and solid tumor programs, , the potential benefits of any of the Company’s proprietary platforms, multiplexing, or current or future product candidates in treating patients, and the Company’s goals and strategy. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “advance,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan’s TCR-T therapy candidates; TScan’s expectations regarding its preclinical studies being predictive of clinical trial results; TScan’s recently approved INDs being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the timing of the launch, initiation, progress and expected results and announcements of TScan’s preclinical studies, clinical trials and its research and development programs; TScan’s timeline regarding its filing of INDs for its TCRs throughout the year, TScan’s ability to enroll patients for its clinical trials within its expected timeline, TScan’s plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
[email protected]

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
[email protected]

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f691bfc7-f775-4112-afc2-99fc7ca1f8cf



Amplify Energy Commences Restart Operations at Beta Field

HOUSTON, April 10, 2023 (GLOBE NEWSWIRE) — Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) today announced that it has received the required approvals from federal regulatory agencies to restart operations at the Beta Field. Initial steps to resume full operations will involve filling the San Pedro Bay Pipeline with production, a process which commenced over the past weekend and is expected to take approximately two weeks to complete. Following the line fill process, the pipeline will be operated in accordance with the restart procedures that were reviewed and approved by the Pipeline and Hazardous Materials Safety Administration (PHMSA).

Martyn Willsher, Amplify’s President and Chief Executive Officer, commented, “Safety has driven every aspect of our response, repair and restart operations, and safety will continue to guide our operating philosophy as we bring the Beta asset back online. The approval from federal regulatory agencies and the receipt of $85 million in net proceeds from the vessels that struck and damaged our pipeline substantially concludes a very challenging last 18 months for the Company, and we are eager to focus our attention on safely operating our Beta assets, our business as a whole and the strategic direction of the Company. Amplify has operated off the coast of California for years in a safe and responsible manner, and we remain committed to ensuring the protection of our employees, the environment and our surrounding communities.”

About Amplify Energy

Amplify Energy Corp. is an independent oil and natural gas company engaged in the acquisition, development, exploitation and production of oil and natural gas properties. Amplify’s operations are focused in Oklahoma, the Rockies (Bairoil), federal waters offshore Southern California (Beta), East Texas / North Louisiana, and the Eagle Ford (Non-op). For more information, visit www.amplifyenergy.com.

Investor Relations Contact

Martyn Willsher – President and Chief Executive Officer
(832) 219-9047
[email protected]

Michael Jordan – Director, Finance and Treasurer
(832) 219-9051
[email protected]

Media Contact

Amy Conway
[email protected]



Broadwind Files Definitive Proxy Statement and Sends Letter to Shareholders

CICERO, Ill., April 10, 2023 (GLOBE NEWSWIRE) — Broadwind, Inc. (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its 2023 annual meeting of stockholders (the “2023 Annual Meeting”), which is scheduled to be held on May 23, 2023 (the “2023 Annual Meeting”). The Company has also sent a letter to shareholders. The full text of the letter follows.

April 10, 2023

Dear Fellow Shareholder, 

Thank you for your investment in Broadwind, Inc. (“Broadwind”). Over the past year, Broadwind took decisive steps to drive value creation for our shareholders. We strengthened our relationships with core wind turbine manufacturing customers and continued to expand into adjacent, high-margin non-wind industries where our innovative manufacturing and engineering capabilities, domestic production facilities, and customer-centric approach remain key areas of competitive differentiation.

As an experienced publicly-traded wind tower manufacturer in the United States, Broadwind is uniquely positioned to benefit from an ongoing, multi-year investment cycle in new onshore wind capacity. We are pleased to report that after a two-year hiatus, activity within the domestic onshore wind market is accelerating entering 2023, as reflected by increased order activity from our wind customers.

These dynamics, coupled with continued stability in our adjacent non-wind markets, put us on pace to achieve near record full-year revenue in 2023. We enter the year with a strong balance sheet, an expanded product line, the highest order and backlog levels in a decade, and historic policy support for wind energy that we are well positioned to leverage.

The 2023 Annual Meeting of Stockholders on May 23, 2023 will be an important one. An activist hedge fund, WM Argyle Fund, LLC (“WM Argyle”), which owns 1.0% of Broadwind’s outstanding common stock valued at approximately $700,000, is seeking to replace three of our directors –half of our independent board, including our Chairman – with a director slate of its own, effectively taking control of your company.

During the past year, WM Argyle has demanded Broadwind undertake a series of high-risk, short-sighted initiatives that exhibit both a lack of commercial sophistication and a fundamentally flawed understanding of the energy transition industry. It has also proposed candidates to the board that we believe are deeply unqualified.

As you cast your vote at the annual meeting this year, we ask you consider the following:

1) Broadwind has successfully navigated through a significant trough in the domestic onshore wind market, positioning the Company for long-term value creation

Wind energy producers have faced a challenging economic environment over the past two years, as pandemic-related supply chain disruptions, raw material price inflation, labor constraints, and softening demand for new renewable energy projects impacted profit margins. The expiration of a US wind energy tax credit in 2020 created further uncertainty, contributing to a decline in new domestic wind turbine installations.

As a trusted partner and supplier to wind turbine original equipment manufacturers (“OEMs”), we supported our customers continuously during a challenging period for the industry. At the same time, we took action to further diversify our revenue mix toward alternative, complementary end markets beyond wind energy such as power generation, oil & gas and infrastructure. In fact, over the last five years, Broadwind grew its annual non-wind revenue by 45% to $90 million through expanded relationships with new and existing partners.

Our strategic focus on revenue diversification has built Broadwind into a more resilient, durable business. We have positioned the business to achieve margin expansion, strengthened our balance sheet, and retained significant manufacturing capacity to support our customers. Our decision to preserve and invest in our manufacturing capabilities has positioned us to respond quickly as market conditions begin to improve across the domestic wind market.

2) Broadwind is a key beneficiary of the Inflation Reduction Act (“IRA”) of 2022, which positions us to deliver significant margin expansion and improved profitability

The IRA of 2022 provides transformative, long-term funding to the domestic wind industry through extended domestic tax credits and transmission infrastructure investments. Importantly, it also offers manufacturers greater visibility into future tax and pricing benefits, facilitating long-term planning and encouraging production of new domestic installations. Following a two-year decline in the pace of wind investment, domestic onshore wind tower installation activity began to accelerate in early 2023. Broadwind is a key beneficiary of this improved market outlook.

To be very clear, this opportunity is not hypothetical. In January 2023, Broadwind announced a transformative $175 million tower order with a major wind turbine OEM. This order more than doubled our backlog and secures at least 50% of our tower production capacity for 2023 and 2024. This order has an attractive margin profile, particularly given the benefit of the IRA-related tax credit.

This transformational order is a validation of our OEM-centric approach, one that led us to preserve capacity that could have been otherwise eliminated and retain skilled labor during the downturn so that we would be among the first to benefit from a rebound in demand entering a cyclical recovery.

We believe investors have recognized our success, together with the significant opportunities that lay ahead for Broadwind. In 2022, Broadwind outperformed the WilderHill Clean Energy Index by 41%. Broadwind’s stock also responded strongly to the recent tower order announcement, contributing to its outperformance versus the WilderHill Clean Energy Index by more than 230% in the three-year period immediately prior to the public activist campaign announcement by WM Argyle on January 18, 2023 and by 90% year-to-date 2023.

3) Broadwind is deploying capital effectively, laying a strong foundation for long-term value creation

Broadwind remains focused on a disciplined capital allocation strategy that supports profitable commercial growth within both existing and adjacent markets, with an emphasis on clean tech and energy transition opportunities.

Looking ahead, we intend to prioritize revenue growth within higher-margin, more profitable areas, while optimizing the economic benefits afforded by the IRA of 2022. Leveraging our high-performance team, we will further enhance the efficiency of our operations, while continuing to invest in people, systems and assets that position us to win in the markets we serve. We will also expand our product lines, creating intellectual property value in clean tech and other specialized markets organically and through accretive, bolt-on acquisitions.

Our new product initiatives have begun to yield positive results. In 2019, we began development of a proprietary technology aligned with our clean tech strategy, which led to the launch of our Medium Flow Pressure Reducing System (PRS) model in 2022, a copyright-protected mobile natural gas decanting system serving the virtual pipeline market in North America. This equipment will allow entry into the hydrogen fuel sector which is currently seeing enormous growth and investment. Our clean fuels product offerings have the potential to be 10% of revenue by 2025.

In 2023, our primary capital allocation priorities include debt reduction; organic investments in new intellectual property; opportunistic return of capital initiatives; and inorganic growth.

Our balance sheet is strong, with a near record level of cash and liquidity as of December 31, 2022 and a prudent net leverage ratio of 0.7x, well within our targeted range of at or below 2.0x. This positions us well to invest in projects that will build long-term value for shareholders.

4) Broadwind’s Board of Directors has the experience and independence required to represent shareholders

Broadwind has a diverse, experienced Board that values best-in-class corporate governance. As a Board, we adopted governance structures such as majority voting and annual elections to increase accountability and transparency to shareholders; an independent Chairman and highly independent Board to enhance oversight of management; and prudent executive compensation programs to align management incentives with the sustainable creation of long-term shareholder value.

Each of our directors has the skills and varied perspectives required to effectively oversee the company’s strategy and risk management. Our candidates offer extensive experience as senior operating and financial executives and public company directors, deep industry expertise in clean technologies and energy transition manufacturing, and broad backgrounds in sales and marketing, accounting, finance, M&A, new product development and risk management.

We are also committed to bringing new perspectives into the boardroom as our business needs evolve. Since the 2022 annual meeting, we have added two extremely talented, qualified directors, each of whom was chosen following a rigorous selection process: Sachin Shivaram, Chief Executive Officer of Wisconsin Aluminum Foundry, and Jeanette Press, who served as the Chief Financial Officer and Principal Accounting Officer for CMC Materials, Inc. (Nasdaq: CCMP).

5) WM Argyle’s activist campaign for Board control is highly disruptive and a serious risk to long-term shareholder value

The contrast between WM Argyle’s candidates and our directors could not be more evident. None of WM Argyle’s nominees have backgrounds in clean technologies or energy transition manufacturing; none have senior executive or public board experience; and none have senior-level financial expertise, or any such background required to be an effective director at Broadwind. Replacing any of our directors with members of WM Argyle’s proposed director slate would result in a significant loss of institutional knowledge and senior-level expertise, jeopardizing the Board’s ability to oversee the successful execution of our strategy.

This inexperience is further evident in the short-sighted, opportunistic proposals put forth by WM Argyle. Despite our significant concerns, over the past year, we have tried in earnest to achieve a viable, constructive resolution with WM Argyle and, in so doing, avoid a costly and distracting proxy contest. The Board thoroughly considered its proposals and candidates. At every point, WM Argyle insisted that the Board relinquish control of Broadwind without a shareholder vote. While the Board has and will always remain open to constructive discussions with Broadwind’s shareholders, it will never abdicate its responsibility to properly represent the interests of all shareholders.

In summary, the election of WM Argyle’s proposed slate would be highly detrimental to your best interests as a shareholder of Broadwind. The Board’s long-term strategic approach clearly positions Broadwind for success, and yielding to WM Argyle’s demands would derail Broadwind’s progress. We look forward to further presenting the facts around WM Argyle’s self-serving campaign over the coming weeks.

We are grateful for the trust you have placed with us as stewards of shareholder capital over the years and ask for your continued support at this annual meeting.

Sincerely,

The Broadwind Board of Directors

ABOUT BROADWIND

Broadwind (NASDAQ: BWEN) is a precision manufacturer of structures, equipment and components for clean tech and other specialized applications. With facilities throughout the U.S., our talented team is committed to helping customers maximize performance of their investments—quicker, easier and smarter. Find out more at www.bwen.com

FORWARD-LOOKING STATEMENTS

This release contains “forward looking statements”—that is, statements related to future, not past, events—as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that reflect the Company’s current expectations regarding its future growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities, as well as assumptions made by, and information currently available to, its management. Forward looking statements include any statement that does not directly relate to a current or historical fact. The Company has tried to identify forward looking statements by using words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “should,” “may,” “plan” and similar expressions, but these words are not the exclusive means of identifying forward looking statements.

The Company’s forward-looking statements may include or relate to the Company’s beliefs, expectations, plans and/or assumptions with respect to the future of the Company’s operations and its ability to continue to execute on its strategies and grow its business organically. These statements are based on information currently available to the Company and are subject to various risks, uncertainties and other factors that could cause the Company’s actual growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities to differ materially from those expressed in, or implied by, these statements including, but not limited to, those set forth under the caption “Risk Factors” in Part I, Item 1A of the Company’s most recently filed Form 10-K and the Company’s other filings with the SEC. The Company is under no duty to update any of these statements. You should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or other factors that could cause the Company’s current beliefs, expectations, plans and/or assumptions to change. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results.

Important Additional Information

The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from the Company’s stockholders in connection with its upcoming 2023 Annual Meeting. The Company filed its definitive proxy statement and a WHITE proxy card with the SEC on April 7, 2023 in connection with any such solicitation of proxies from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company’s definitive proxy statement for the 2023 Annual Meeting contains information regarding the direct and indirect interests, by security holdings or otherwise, of the Company’s directors and executive officers in the Company’s securities. Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4 and 5, which are available on the Company’s website at http://investors.bwen.com or through the SEC’s website at www.sec.gov. Information can also be found in the Company’s other SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 9, 2023. Stockholders will be able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge on the Company’s website at http://investors.bwen.com.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/fa86d1d6-926c-49b7-95b4-4d6323e481e8

https://www.globenewswire.com/NewsRoom/AttachmentNg/572579d5-a129-4a49-816d-25793239915f 



CORPORATE CONTACT

Noel Ryan, IRC
[email protected] 

SHAREHOLDER CONTACT

Morrow Sodali LLC
(800) 662-5200
[email protected] 

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., April 10, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 20,000 shares of its common stock with an exercise price of $2.76, which is equal to the closing price of Gritstone’s common stock on April 3, 2023, the date of the grant. These stock options are part of an inducement material to the new employee becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees’ date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees’ continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone’s 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

About Gritstone bio

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com


Gritstone Contacts


Investors:
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
[email protected]

Media:
Dan Budwick
1AB
(973) 271-6085
[email protected]



Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

The Pivotal Study is Aimed to Support a Marketing Authorization Application

PETACH TIKVA, Israel,–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) with respect to the submission of a registration plan for a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis. The pivotal Phase III study and the safety of the 3 mg twice daily dose of Piclidenoson are accepted by the agency.

The Company intends to initiate a prospective double-blind, placebo-controlled and randomized clinical trial with its lead product Piclidenoson aimed at demonstrating clinical safety and efficacy for the treatment of moderate to severe psoriasis sufficient to support a marketing authorization application.

The agency also commented on the registration plan submitted by the Company relating to the chemistry, manufacturing, and controls (CMC), nonclinical data, and clinical pharmacology data. Can-Fite is currently submitting a comparable data package to the US Food and Drug Administration.

Can-Fite recently reported topline results from its Phase III COMFORT™ study which met its primary endpoint with statistically significant improvement over placebo in psoriasis patients and an excellent safety profile for Piclidenoson.

“Piclidenoson’s oral dosage and excellent safety record combined with its progressive effectiveness over time make it ideally suited for the treatment of psoriasis, a chronic disease. Should this market registration study produce positive results similar to our COMFORT study, we believe Piclidenoson will be well positioned in a very large market which needs more safe and effective oral drug options,” stated Can-Fite CEO Dr. Pnina Fishman.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment is expected to commence in a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 30, 2023 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Can-Fite BioPharma

Motti Farbstein

[email protected]

+972-3-9241114

KEYWORDS: New York North America United States Europe Middle East Israel

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Oncology General Health Health FDA Clinical Trials Other Health

MEDIA:

Logo
Logo